AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

AGEN · NASDAQ · Biotechnology

Agenus

Develops investigational BOT+BAL antibodies for colorectal cancer and selected tumors.

$7.66

After-hours close0.00 (0.00%)

At close$7.66(−1.92%)

Something off on this page? Send us feedback.

Profile

Agenus Inc.AGENHealth Care

Develops BOT+BAL, an investigational anti-CTLA-4 and anti-PD-1 antibody combination for colorectal cancer and selected tumors. The clinical-stage immuno-oncology company combines internal development capabilities with selected collaborations and retained manufacturing capacity.

Develops BOT+BAL, an investigational combination of botensilimab, an anti-CTLA-4 antibody, and balstilimab, an anti-PD-1 antibody. The lead program is being developed for colorectal cancer and selected other tumors; neither component is approved for commercial sale.

Discovery and development combine internal translational, clinical, and regulatory work with selected collaborations. Earlier vaccine, adjuvant, and checkpoint-antibody programs inform a portfolio that the company narrowed after its strategic realignment.

Manufacturing flexibility depends on the Zydus collaboration, which provides committed capacity at transferred U.S. biologics facilities. Progress toward registration and commercialization depends on additional capital and regulatory development.

Company facts

CEOGaro H. Armen, Ph.D.

ListedFeb 4, 2000

ExchangeNASDAQ

HeadquartersLexington, MA

CountryUnited States

Employees81

CIK0001098972

ISINUS00847G8042

Key statistics

Market cap$319.0M

EPS (ttm)$2.65

P/E (ttm)2.90

ROE-38.1%

P/B−1.59

P/S2.40

Dividend yield—

Beta1.55vs XLV 1.41

Year to date +137% · Average volume (30d) 1.6M

Analysts

Price target, next 12 months$25.00+226.4%Median of 11 analysts · vs the Aug 28 close

ConsensusBuy9 of 11 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $7.66

High$25.00+226.4%

Median$25.00+226.4%

Low$25.00+226.4%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior rating	Rating	Prior target	Target
Aug 11, 2026	H.C. Wainwright	Reiterate		Buy	$7	$25
Jun 4, 2025	H.C. Wainwright	Upgrade	Neutral	Buy
Jun 4, 2025	HC Wainwright & Co.	Upgrade	Neutral	Buy

Earnings

EPS

Estimate$0.02

ReportedDue Nov 9, 2026

Revenue

Estimate$35.0M

ReportedDue Nov 9, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 6, 2026Q2 FY26	$0.05	−$0.01	−122.2%	$34.0M	$34.5M	+1.5%	−3.73%
May 11, 2026Q1 FY26	$2.10	$1.02	−51.4%	$129.5M	$33.7M	−74.0%	+5.52%
Mar 16, 2026Q4 FY25	−$1.27	$0.56	+144.1%	$28.1M	$34.2M	+21.7%	+21.28%
Nov 10, 2025Q3 FY25	$2.63	$1.94	−26.2%	$28.1M	$30.2M	+7.6%	+1.43%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$24.1M	$25.7M	$30.2M	$34.2M	$33.7M	$34.5M
Gross profit	$2.4M	−$1.3M	$6.0M	$26.7M	$33.2M	$34.5M
Operating income	−$13.3M	−$16.7M	−$4.5M	$14.4M	$15.1M	$11.3M
Net income	−$25.3M	−$28.0M	$63.9M	−$10.6M	$39.2M	−$550.0K
Diluted EPS	−$1.03	−$1.00	$1.94	−$0.30	$1.02	−$0.01
Gross margin	10.0%	-4.9%	19.8%	78.0%	98.3%	100.0%
Operating margin	-55.3%	-65.0%	-15.0%	42.1%	44.6%	32.7%

Fiscal years (4-quarter sums)FY21 $295.7M · FY22 $98.0M · FY23 $156.3M · FY24 $103.5M · FY25 $114.2M

Revenue by product · Q2 FY26

Non Cash Royalty Revenue$28.1M · 100%

Revenue by geography · Q2 FY26

United States$34.5M · 100%

Balance sheet, Jun 30, 2026Cash & short-term investments $18.7M · Total debt $40.7M · Total assets $172.7M · Shareholders' equity −$199.1M

Dividends

No dividends on record.

Ownership

Institutions 34.52%14.38M sharesInsiders 1.27%528.1K sharesOther 64.21%26.74M shares

Shares outstanding 41.64M · Float 37.19M · 89.3% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
RA Capital Management, L.P.	4.34M	9.90%	13G	Jul 20, 2026
Invus Public Equities, L.P.	3.97M	8.80%	13G	Jul 17, 2026
BlackRock, Inc.	2.51M	6.00%	13G	Jul 27, 2026
Zynext Ventures USA LLC	2.13M	5.90%	13D	Jan 23, 2026
Vanguard Capital Management LLC	1.68M	4.02%	13F	Aug 13, 2026

Insider tradesForm 4

No open-market trades in the last 12 months.